IND Swift Laboratories Ltd
ISLB.IN
$1.49
Closing
▲1.02%
1D
▲20.09%
YTD
Market cap
$88.18M
52 week high
$1.66
52 week low
$0.77
Volume
454,643
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$88.18M
Analysts' Rating
-
Price Target (Mean)
Unable to collect data for some field(s).
Total Analysts
0
P/E
16.99
Operating Margin
18.12%
Beta
-0.06
Revenue Growth (Annual)
7.87%
52 week high
$1.66
52 week low
$0.77
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.
